Synergism between SLC6A14 blockade and gemcitabine in pancreactic cancer: a 1H-NMR-based metabolomic study in pancreatic cancer cells
Open Access
- 29 May 2020
- journal article
- research article
- Published by Portland Press Ltd. in Biochemical Journal
- Vol. 477 (10), 1923-1937
- https://doi.org/10.1042/bcj20200275
Abstract
Gemcitabine is the first-line chemotherapy for pancreatic cancer. To overcome the often-acquired gemcitabine resistance, other drugs are used in combination with gemcitabine. It is well-known that cancer cells reprogram cellular metabolism, coupled with the upregulation of selective nutrient transporters to feed into the altered metabolic pathways. Our previous studies have demonstrated that the amino acid transporter SLC6A14 is markedly upregulated in pancreatic cancer and that it is a viable therapeutic target. α-Methyltryptophan (α-MT) is a blocker of SLC6A14 and is effective against pancreatic cancer in vitro and in vivo. In the present study, we tested the hypothesis that α-MT could synergize with gemcitabine in the treatment of pancreatic cancer. We investigated the effects of combination of α-MT and gemcitabine on proliferation, migration, and apoptosis in a human pancreatic cancer cell line, and examined the underlying mechanisms using 1H-NMR-based metabolomic analysis. These studies examined the intracellular metabolite profile and the extracellular metabolite profile separately. Combination of α-MT with gemcitabine elicited marked changes in a wide variety of metabolic pathways, particularly amino acid metabolism with notable alterations in pathways involving tryptophan, branched-chain amino acids, ketone bodies, and membrane phospholipids. The metabolomic profiles of untreated control cells and cells treated with gemcitabine or α-MT were distinctly separable, and the combination regimen showed a certain extent of overlap with the individual α-MT and gemcitabine groups. This represents the first study detailing the metabolomic basis of the anti-cancer efficacy of gemcitabine, α-MT and their combination.This publication has 48 references indexed in Scilit:
- Systematic Applications of Metabolomics in Metabolic EngineeringMetabolites, 2012
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not AnticipateCancer Cell, 2012
- Choline metabolism in malignant transformationNature Reviews Cancer, 2011
- SLC6A14 (ATB0,+) Protein, a Highly Concentrative and Broad Specific Amino Acid Transporter, Is a Novel and Effective Drug Target for Treatment of Estrogen Receptor-positive Breast CancerOnline Journal of Public Health Informatics, 2011
- Fermentanomics: Monitoring Mammalian Cell Cultures with NMR SpectroscopyJournal of the American Chemical Society, 2010
- Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 StudyJournal of Clinical Oncology, 2010
- Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyondPharmacology & Therapeutics, 2009
- Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapyBiochemical Journal, 2008
- Up-regulation of the amino acid transporter ATB0,+ (SLC6A14) in carcinoma of the cervixGynecologic Oncology, 2006
- Upregulation of the amino acid transporter ATB0,+ (SLC6A14) in colorectal cancer and metastasis in humansBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2005